Primary sclerosing cholangitis (PSC) and tamoxifen

E. Scapa*, R. Orda

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


There is no effective medical treatment for primary sclerosing cholangitis (PSC). Tamoxifen was found to have anti-fibrotic properties and has only few and rare side-effects. We gave 6 PSC patients 20 mg/day of tamoxifen and we studied its influence on the alkaline phosphatase (ALP) serum levels. Duration of treatment was from 1 to 8 months. Two patients showed a decline of their ALP to normal values, the other 4 patients showed improvement. Our results are encouraging and a larger scale study for a longer period of time is needed to evaluate the effect of tamoxifen on PSC patients. In such a study, liver biopsies should be performed for histological evaluation.

Original languageEnglish
Pages (from-to)149-152
Number of pages4
JournalInternational Hepatology Communications
Issue number3
StatePublished - Sep 1995
Externally publishedYes


  • Primary sclerosing cholangitis
  • Tamoxifen


Dive into the research topics of 'Primary sclerosing cholangitis (PSC) and tamoxifen'. Together they form a unique fingerprint.

Cite this